Moklobemīds

Moclobemide is a reversible inhibitor of monoamine oxidase A (RIMA) primarily used for depression and social anxiety. Unlike irreversible MAOIs, it has significantly lower tyramine interaction risk and does not require strict dietary restrictions at therapeutic doses, though caution is still advised. The drug has minimal anticholinergic, cardiovascular, and cognitive side effects, making it suitable for elderly patients. It is considered safe in overdose when taken alone, but potentially fatal when combined with serotonergic agents. Not approved in the United States.

Also known as: Rima, Amira, Depnil, Aurorix, Manerix, Aurorex, Ro 11-1163

Classification

Chemical: Medicine
Tag: Antidepressant
Tag: Benzamide
Tag: MAOI
Tag: Morpholine derivative
Tag: Pharmaceutical

Effects

Anxiolysis
Increased Energy
Insomnia Or Sleep Disturbances
Restlessness
Nausea
Headache
Mood Elevation
Improved Motivation
Enhanced Sociability
Dizziness
Euphoria
Anxiety Suppression
Dulled Perception
Appetite Suppression
Sexual Dysfunction
Light Sensitivity
Disinhibition
Tactile Suppression

Routes of Administration

Oral

Dosage

Threshold: 50 mg
Light: 150-300 mg
Common: 300–600 mg/day (divided)
Strong: 600–900 mg/day (divided)
Heavy: ≥900 mg/day (divided)

Duration

Onset: 0.5-1.5 h
Comeup: 1-2 h
Peak: 2-4 h
Offset: 8-10 h
After Effects: 16-24 h
Total Duration: 8-16 h

Harm Reduction

Check interactions before mixing substances, pay attention to dose spacing and hydration, and treat all dosage guidance as approximate rather than guaranteed safe.

Sources

Substance data is aggregated from the following public harm-reduction and reference sources.

Links

This static page is intended as a readable non-JS and prerender-friendly library export.

Get the full DrugsPRO experience

Open the interactive DrugsPRO app for search, saved items, interactions, and deeper harm reduction tools.

Get the PRO test kit. The simple, quick and reliable drug checking test kit. Visit https://protestkit.eu